Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon._老虎社区_美港股上老虎

Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.

Motley Fool04-24

Novo Nordisk has achieved tremendous success thanks largely to Ozempic and Wegovy. Vertex Pharmaceuticals is another drugmaker that could soon have two new big winners on the market. ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

红运2022
·04-25
这篇文章不错，转发给大家看看
回复
点赞
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2429480258?lang=zh_CN&edition=full","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F773900%2Fyoung-woman-frustrated-laptop.jpg&op=resize&w=165&h=104","is_english":true,"pubTime":"2024-04-24 17:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2429480258","market":"fut","top_or_hot":-1,"title":"Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.","media":"Motley Fool","content":"<div>\n<p>Novo Nordisk has achieved tremendous success thanks largely to Ozempic and Wegovy.\n\n\n\n\n\n\n\nVertex Pharmaceuticals is another drugmaker that could soon have two new big winners on the market.\n\n\n\n\n\n\n\n...</p>\n\n<a href=\"https://www.fool.com/investing/2024/04/24/missed-out-on-novo-nordisk-2-healthcare-stocks-wit/\">网页链接</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMissed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-24 17:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2024/04/24/missed-out-on-novo-nordisk-2-healthcare-stocks-wit/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novo Nordisk has achieved tremendous success thanks largely to Ozempic and Wegovy.\n\n\n\n\n\n\n\nVertex Pharmaceuticals is another drugmaker that could soon have two new big winners on the market.\n\n\n\n\n\n\n\n...</p>\n\n<a href=\"https://www.fool.com/investing/2024/04/24/missed-out-on-novo-nordisk-2-healthcare-stocks-wit/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0002270589.USD","symbol_name":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","start_time":0,"source_url":"https://www.fool.com/investing/2024/04/24/missed-out-on-novo-nordisk-2-healthcare-stocks-wit/","article_id":"2429480258","we_media_id":null,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F773900%2Fyoung-woman-frustrated-laptop.jpg&op=resize&w=165&h=104"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2429480258","pubTimestamp":1713952200,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Good news could be just around the corner for two drugmakers not named Novo Nordisk.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","VRTX":"福泰制药","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","HCSG":"医疗保健服务","CF":"CF工业","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0079474960.USD":"联博美国增长基金A","BK4585":"ETF&股票定投概念","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","BK4023":"应用软件","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4137":"综合支持服务","BK4532":"文艺复兴科技持仓","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4567":"ESG概念","BK4093":"化肥与农用药剂","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","VERX":"Vertex, Inc.","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4588":"碎股","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4139":"生物科技","NVO":"诺和诺德","LU0058720904.USD":"联博国际健康护理基金A","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD"},"translate_title":"错过了诺和诺德？2医疗保健股即将迎来巨大的催化剂。","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1,"CF":1,"HCSG":1,"VRTX":0.9,"VERX":0.9},"content_text":"Novo Nordisk has achieved tremendous success thanks largely to Ozempic and Wegovy.\n\n\n\n\n\n\n\nVertex Pharmaceuticals is another drugmaker that could soon have two new big winners on the market.\n\n\n\n\n\n\n\nViking Therapeutics has key potential catalysts coming soon for its promising NASH and X-ALD therapies.\n\nOzempic and Wegovy are the rock stars of the biopharmaceutical world. When celebrities talk about a prescription drug, it has reached the big time. And that's what has happened with Novo Nordisk's two blockbusters. The success of Ozempic and Wegovy has also helped Novo Nordisk become a rock star for investors. Shares of the big drugmaker have skyrocketed nearly 240% over the last three years.Don't worry if you think you've missed out on Novo Nordisk, though. Here are two healthcare stocks with big catalysts on the horizon.1. Vertex PharmaceuticalsVertex Pharmaceuticals (VRTX 1.25%) doesn't have celebrities name-dropping its products, but it has achieved tremendous success. The big biotech markets the only therapies that treat the underlying cause of cystic fibrosis (CF). Vertex, along with its partner CRISPR Therapeutics, also now has the first (and so far only) CRISPR gene-editing therapy on the market.We might not have to wait long for Vertex to add to its success story. The company has already submitted the first module to the U.S. Food and Drug Administration (FDA) in a rolling submission for suzetrigine (formerly known as VX-548) in treating acute pain. Vertex expects to complete the full filing by the end of the second quarter of 2024.Acute pain represents a multibillion-dollar market dominated by anti-inflammatory drugs that are safe but have limited efficacy and opioids that are effective but have a high potential for addiction. Suzetrigine uses a novel method of alleviating pain (inhibiting a pain signal inhibitor called NaV1.8) that's effective and safe without addictive qualities. Vertex also has another regulatory filing on the way this summer for its vanzacaftor/tezacaftor/deutivacaftor combination therapy targeting CF. This triple-drug combo was as good as or better than the company's top-selling CF drug, Trikafta, in phase 3 testing. Because of the vanzacaftor therapy's convenient once-daily dosing and its significantly lower royalty burden, I expect it will become Vertex's most profitable CF therapy yet if approved. 2. Viking TherapeuticsIf you want a big opportunity in the obesity market along the lines of what Novo Nordisk has experienced, Viking Therapeutics (VKTX 1.69%) could be a great pick for you. And Viking's obesity drugs just might be better than Novo's Wegovy.In February, Viking announced overwhelmingly positive results from a phase 2 study of VK2735. Patients receiving the experimental drug achieved up to 13.1% placebo-adjusted mean weight loss after 13 weeks of treatment. These results were more impressive than those seen in the clinical trials of Wegovy and Eli Lilly's Zepbound. One month later, Viking reported more good news for VK2735. This time it was with an oral version of the weight-loss drug. The company announced positive results from a phase 1 study. Perhaps most encouraging was the oral formulation of VK2735 had low rates of gastrointestinal-related side effects. But the next big catalyst for Viking could come from other pipeline candidates. The clinical-stage biotech expects to announce histology results from a phase 1 study evaluating VK2809 in treating nonalcoholic steatohepatitis (NASH) and fibrosis by mid-2024. It also should report results from a phase 1b study of VK0214 in treating rare neurodegenerative disease X-linked adrenoleukodystrophy (X-ALD).","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[{"id":298796162846720,"gmtCreate":1713977556818,"gmtModify":1713977558537,"author":{"id":"4118205146243860","authorId":"4118205146243860","name":"红运2022","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":7,"crmLevelSwitch":0},"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/298796162846720","repostId":2429480258,"repostType":2,"repost":{"id":"2429480258","pubTimestamp":1713952200,"share":"https://www.laohu8.com/m/news/2429480258?lang=&edition=full","pubTime":"2024-04-24 17:50","market":"fut","language":"en","title":"Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.","url":"https://stock-news.laohu8.com/highlight/detail?id=2429480258","media":"Motley Fool","summary":"Good news could be just around the corner for two drugmakers not named Novo Nordisk.","content":"<html><body><ul>\n<li>\n<div>\n<svg fill=\"none\" height=\"15\" viewbox=\"0 0 14 15\" width=\"14\" xmlns=\"http://www.w3.org/2000/svg\">\n<path d=\"M14 5.58984C14 2.91016 11.8398 0.75 9.16016 0.75C6.50781 0.777344 4.375 2.91016 4.375 5.5625C4.375 6.10938 4.45703 6.60156 4.59375 7.09375L0.191406 11.4961C0.0546875 11.6328 0 11.7969 0 11.9609V14.0938C0 14.4766 0.273438 14.75 0.65625 14.75H3.71875C4.07422 14.75 4.375 14.4766 4.375 14.0938V13H5.46875C5.82422 13 6.125 12.7266 6.125 12.3438V11.25H7.13672C7.30078 11.25 7.51953 11.168 7.62891 11.0312L8.28516 10.293C8.55859 10.3477 8.85938 10.375 9.1875 10.375C11.8398 10.375 14 8.24219 14 5.58984ZM9.1875 4.25C9.1875 3.53906 9.76172 2.9375 10.5 2.9375C11.2109 2.9375 11.8125 3.53906 11.8125 4.25C11.8125 4.98828 11.2109 5.5625 10.5 5.5625C9.76172 5.5625 9.1875 4.98828 9.1875 4.25Z\" fill=\"#FFB81C\"></path>\n</svg>\n</div>\n<div>Novo Nordisk has achieved tremendous success thanks largely to Ozempic and Wegovy.</div>\n</li>\n<li>\n<div>\n<svg fill=\"none\" height=\"15\" viewbox=\"0 0 14 15\" width=\"14\" xmlns=\"http://www.w3.org/2000/svg\">\n<path d=\"M14 5.58984C14 2.91016 11.8398 0.75 9.16016 0.75C6.50781 0.777344 4.375 2.91016 4.375 5.5625C4.375 6.10938 4.45703 6.60156 4.59375 7.09375L0.191406 11.4961C0.0546875 11.6328 0 11.7969 0 11.9609V14.0938C0 14.4766 0.273438 14.75 0.65625 14.75H3.71875C4.07422 14.75 4.375 14.4766 4.375 14.0938V13H5.46875C5.82422 13 6.125 12.7266 6.125 12.3438V11.25H7.13672C7.30078 11.25 7.51953 11.168 7.62891 11.0312L8.28516 10.293C8.55859 10.3477 8.85938 10.375 9.1875 10.375C11.8398 10.375 14 8.24219 14 5.58984ZM9.1875 4.25C9.1875 3.53906 9.76172 2.9375 10.5 2.9375C11.2109 2.9375 11.8125 3.53906 11.8125 4.25C11.8125 4.98828 11.2109 5.5625 10.5 5.5625C9.76172 5.5625 9.1875 4.98828 9.1875 4.25Z\" fill=\"#FFB81C\"></path>\n</svg>\n</div>\n<div>Vertex Pharmaceuticals is another drugmaker that could soon have two new big winners on the market.</div>\n</li>\n<li>\n<div>\n<svg fill=\"none\" height=\"15\" viewbox=\"0 0 14 15\" width=\"14\" xmlns=\"http://www.w3.org/2000/svg\">\n<path d=\"M14 5.58984C14 2.91016 11.8398 0.75 9.16016 0.75C6.50781 0.777344 4.375 2.91016 4.375 5.5625C4.375 6.10938 4.45703 6.60156 4.59375 7.09375L0.191406 11.4961C0.0546875 11.6328 0 11.7969 0 11.9609V14.0938C0 14.4766 0.273438 14.75 0.65625 14.75H3.71875C4.07422 14.75 4.375 14.4766 4.375 14.0938V13H5.46875C5.82422 13 6.125 12.7266 6.125 12.3438V11.25H7.13672C7.30078 11.25 7.51953 11.168 7.62891 11.0312L8.28516 10.293C8.55859 10.3477 8.85938 10.375 9.1875 10.375C11.8398 10.375 14 8.24219 14 5.58984ZM9.1875 4.25C9.1875 3.53906 9.76172 2.9375 10.5 2.9375C11.2109 2.9375 11.8125 3.53906 11.8125 4.25C11.8125 4.98828 11.2109 5.5625 10.5 5.5625C9.76172 5.5625 9.1875 4.98828 9.1875 4.25Z\" fill=\"#FFB81C\"></path>\n</svg>\n</div>\n<div>Viking <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> has key potential catalysts coming soon for its promising NASH and X-ALD therapies.</div>\n</li>\n</ul><div><p>Ozempic and Wegovy are the rock stars of the biopharmaceutical world. When celebrities talk about a prescription drug, it has reached the big time. And that's what has happened with <strong>Novo Nordisk</strong>'s two blockbusters<strong>. </strong></p><p>The success of Ozempic and Wegovy has also helped Novo Nordisk become a rock star for investors. Shares of the big drugmaker have skyrocketed nearly 240% over the last three years.</p><p>Don't worry if you think you've missed out on Novo Nordisk, though. Here are two healthcare stocks with big catalysts on the horizon.</p><h2>1. Vertex Pharmaceuticals</h2><p><strong>Vertex Pharmaceuticals</strong> <span>(VRTX<span> 1.25%</span>)</span> doesn't have celebrities name-dropping its products, but it has achieved tremendous success. The big biotech markets the only therapies that treat the underlying cause of cystic fibrosis (CF). Vertex, along with its partner <strong>CRISPR Therapeutics</strong>, also now has the first (and so far only) CRISPR gene-editing therapy on the market.</p><div><app :collapse_on_load=\"false\" :instrument_id=\"206020\" :show_benchmark_compare=\"false\" amount_change=\"4.99\" average_volume=\"1,219,252\" company_name=\"Vertex Pharmaceuticals\" current_price=\"404.91\" daily_high=\"406.86\" daily_low=\"403.47\" default_period=\"OneYear\" dividend_yield=\"N/A\" exchange=\"NASDAQ\" fifty_two_week_high=\"448.40\" fifty_two_week_low=\"316.43\" gross_margin=\"87.17\" logo=\"https://g.foolcdn.com/art/companylogos/mark/VRTX.png\" market_cap=\"$105B\" pe_ratio=\"29.15\" percent_change=\"1.25\" symbol=\"VRTX\" volume=\"5\"></app></div><p>We might not have to wait long for Vertex to add to its success story. The company has already submitted the first module to the U.S. Food and Drug Administration (FDA) in a rolling submission for suzetrigine (formerly known as VX-548) in treating acute pain. Vertex expects to complete the full filing by the end of the second quarter of 2024.</p><div><div></div></div><p>Acute pain represents a multibillion-dollar market dominated by anti-inflammatory drugs that are safe but have limited efficacy and opioids that are effective but have a high potential for addiction. Suzetrigine uses a novel method of alleviating pain (inhibiting a pain signal inhibitor called NaV1.8) that's effective and safe without addictive qualities. </p><p>Vertex also has another regulatory filing on the way this summer for its vanzacaftor/tezacaftor/deutivacaftor combination therapy targeting CF. This triple-drug combo was as good as or better than the company's top-selling CF drug, Trikafta, in phase 3 testing. Because of the vanzacaftor therapy's convenient once-daily dosing and its significantly lower royalty burden, I expect it will become Vertex's most profitable CF therapy yet if approved. </p><h2>2. Viking Therapeutics</h2><p>If you want a big opportunity in the obesity market along the lines of what Novo Nordisk has experienced, <strong>Viking Therapeutics</strong> <span>(VKTX<span> 1.69%</span>)</span> could be a great pick for you. And Viking's obesity drugs just might be better than Novo's Wegovy.</p><div><app :collapse_on_load=\"false\" :instrument_id=\"335108\" :show_benchmark_compare=\"false\" amount_change=\"1.08\" average_volume=\"6,400,240\" company_name=\"Viking Therapeutics\" current_price=\"64.93\" daily_high=\"67.58\" daily_low=\"63.51\" default_period=\"OneYear\" dividend_yield=\"N/A\" exchange=\"NASDAQ\" fifty_two_week_high=\"99.41\" fifty_two_week_low=\"8.28\" gross_margin=\"0.00\" logo=\"https://g.foolcdn.com/art/companylogos/mark/VKTX.png\" market_cap=\"$7B\" pe_ratio=\"-70.97\" percent_change=\"1.69\" symbol=\"VKTX\" volume=\"496\"></app></div><p>In February, Viking announced overwhelmingly positive results from a phase 2 study of VK2735. Patients receiving the experimental drug achieved up to 13.1% placebo-adjusted mean weight loss after 13 weeks of treatment. These results were more impressive than those seen in the clinical trials of Wegovy and <strong>Eli Lill</strong>y's Zepbound. </p><div><div></div></div><p>One month later, Viking reported more good news for VK2735. This time it was with an oral version of the weight-loss drug. The company announced positive results from a phase 1 study. Perhaps most encouraging was the oral formulation of VK2735 had low rates of gastrointestinal-related side effects. </p><p>But the next big catalyst for Viking could come from other pipeline candidates. The clinical-stage biotech expects to announce histology results from a phase 1 study evaluating VK2809 in treating nonalcoholic steatohepatitis (NASH) and fibrosis by mid-2024. It also should report results from a phase 1b study of VK0214 in treating rare neurodegenerative disease X-linked adrenoleukodystrophy (X-ALD). </p><div></div></div></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMissed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-24 17:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2024/04/24/missed-out-on-novo-nordisk-2-healthcare-stocks-wit/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novo Nordisk has achieved tremendous success thanks largely to Ozempic and Wegovy.\n\n\n\n\n\n\n\nVertex Pharmaceuticals is another drugmaker that could soon have two new big winners on the market.\n\n\n\n\n\n\n\n...</p>\n\n<a href=\"https://www.fool.com/investing/2024/04/24/missed-out-on-novo-nordisk-2-healthcare-stocks-wit/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F773900%2Fyoung-woman-frustrated-laptop.jpg&op=resize&w=165&h=104","relate_stocks":{"IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","VRTX":"福泰制药","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","HCSG":"医疗保健服务","CF":"CF工业","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0079474960.USD":"联博美国增长基金A","BK4585":"ETF&股票定投概念","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","BK4023":"应用软件","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4137":"综合支持服务","BK4532":"文艺复兴科技持仓","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4567":"ESG概念","BK4093":"化肥与农用药剂","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","VERX":"Vertex, Inc.","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4588":"碎股","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4139":"生物科技","NVO":"诺和诺德","LU0058720904.USD":"联博国际健康护理基金A","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD"},"source_url":"https://www.fool.com/investing/2024/04/24/missed-out-on-novo-nordisk-2-healthcare-stocks-wit/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2429480258","content_text":"Novo Nordisk has achieved tremendous success thanks largely to Ozempic and Wegovy.\n\n\n\n\n\n\n\nVertex Pharmaceuticals is another drugmaker that could soon have two new big winners on the market.\n\n\n\n\n\n\n\nViking Therapeutics has key potential catalysts coming soon for its promising NASH and X-ALD therapies.\n\nOzempic and Wegovy are the rock stars of the biopharmaceutical world. When celebrities talk about a prescription drug, it has reached the big time. And that's what has happened with Novo Nordisk's two blockbusters. The success of Ozempic and Wegovy has also helped Novo Nordisk become a rock star for investors. Shares of the big drugmaker have skyrocketed nearly 240% over the last three years.Don't worry if you think you've missed out on Novo Nordisk, though. Here are two healthcare stocks with big catalysts on the horizon.1. Vertex PharmaceuticalsVertex Pharmaceuticals (VRTX 1.25%) doesn't have celebrities name-dropping its products, but it has achieved tremendous success. The big biotech markets the only therapies that treat the underlying cause of cystic fibrosis (CF). Vertex, along with its partner CRISPR Therapeutics, also now has the first (and so far only) CRISPR gene-editing therapy on the market.We might not have to wait long for Vertex to add to its success story. The company has already submitted the first module to the U.S. Food and Drug Administration (FDA) in a rolling submission for suzetrigine (formerly known as VX-548) in treating acute pain. Vertex expects to complete the full filing by the end of the second quarter of 2024.Acute pain represents a multibillion-dollar market dominated by anti-inflammatory drugs that are safe but have limited efficacy and opioids that are effective but have a high potential for addiction. Suzetrigine uses a novel method of alleviating pain (inhibiting a pain signal inhibitor called NaV1.8) that's effective and safe without addictive qualities. Vertex also has another regulatory filing on the way this summer for its vanzacaftor/tezacaftor/deutivacaftor combination therapy targeting CF. This triple-drug combo was as good as or better than the company's top-selling CF drug, Trikafta, in phase 3 testing. Because of the vanzacaftor therapy's convenient once-daily dosing and its significantly lower royalty burden, I expect it will become Vertex's most profitable CF therapy yet if approved. 2. Viking TherapeuticsIf you want a big opportunity in the obesity market along the lines of what Novo Nordisk has experienced, Viking Therapeutics (VKTX 1.69%) could be a great pick for you. And Viking's obesity drugs just might be better than Novo's Wegovy.In February, Viking announced overwhelmingly positive results from a phase 2 study of VK2735. Patients receiving the experimental drug achieved up to 13.1% placebo-adjusted mean weight loss after 13 weeks of treatment. These results were more impressive than those seen in the clinical trials of Wegovy and Eli Lilly's Zepbound. One month later, Viking reported more good news for VK2735. This time it was with an oral version of the weight-loss drug. The company announced positive results from a phase 1 study. Perhaps most encouraging was the oral formulation of VK2735 had low rates of gastrointestinal-related side effects. But the next big catalyst for Viking could come from other pipeline candidates. The clinical-stage biotech expects to announce histology results from a phase 1 study evaluating VK2809 in treating nonalcoholic steatohepatitis (NASH) and fibrosis by mid-2024. It also should report results from a phase 1b study of VK0214 in treating rare neurodegenerative disease X-linked adrenoleukodystrophy (X-ALD).","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":2,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}